LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

CRISPR and Coronavirus

30/04/2020
BLOG

CRISPR and the Coronavirus

A recent interview with Prof. Jennifer Doudna, a co-discoverer of the CRISPR-Cas9 system for genome editing, highlights potential applications of the technology to COVID-19.

The CRISPR (Clustered Regularly Interspaced Short Palindromic) genome editing system can be used to delete, insert, or alter any type of DNA/RNA, including that of humans, animals, plants, or microorganisms like bacteria. CRISPR is a highly versatile technique which has the potential to cure complex diseases at the genetic level efficiently.

In the interview with Amanpour and Company, Prof. Doudna discusses some of the recent efforts of her lab at UC Berkley. Together with more than 50 volunteer scientist and data management experts, she transformed part of UC Berkley's Innovative Genomics Institute into a testing facility for COVID-19. Prof. Doudna highlights the solidarity and collaboration of all parties involved:

"Many scientists, myself included […] really want to be contributing our expertise and we're not seeking to profit from it. We're working with university officials to see if we can put out […] a statement about how IP will be managed that comes out of this pandemic, [and] how discoveries can be made openly available".

Asked about the origins of CRISPR and its relation to virus fighting bacteria found naturally in organisms, Prof. Doudna said:

"CRISPR is an adapted immune system, it allows bacteria to detect viruses and protect themselves from future viruses […] a handful of scientists were studying [it and found] we could actually harness it as a technology for something quite different – that's genome editing. Reflecting on this during the pandemic, there's a fascinating parallel that bacteria have had to come up with creative ways to fight [viruses], and now here we are, humans, facing this challenge".

In the current coronavirus pandemic, CRISPR could be utilised in a number of ways. Employing CRISPR is possible as part of diagnostic tests: "enzymes can interact with nucleic acid, which is RNA or DNA, when they do that they turn on an activity […] that allows a big amplification of the signal".

These could, according to Prof. Doudna, be engineered to be carried out as part of at-home testing kits – not dissimilar to a pregnancy test. The benefit of this, aside from taking pressure off healthcare systems, is understanding who is infected and how to keep others safe.

Future applications of CRISPR could see the technology used to fight viruses directly. The lab of Dr. Stanley Qi, a colleague of Prof. Doudna at UC Berkley, has recently been looking at the possibility to develop a prophylactic response to corona and influenza viruses. This technique, based on the CRISPR-Cas9 system, is called PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells).

Prof. Doudna describes this as a clever approach, which could utilise CRISPR against the coronavirus to:

"literally go after […] only the viral RNA, and not RNAs that are present in normal cells".

However this approach is not immediately useful against the coronavirus. Although the technology shows promising results in lab settings, it is necessary to spend more time to achieve a stable delivery method which can appropriately access affected cells in lungs. Read here our blog on how soon we can respond to the coronavirus.

As an increasingly vital part of the biotechnology toolkit in medicine, the versatility of CRISPR continues to be promising. Such innovation and collaboration put the biotechnology industry at the forefront of providing solutions to the novel problems life throws our way!

Sources:
- https://www.youtube.com/watch?v=XzRMcO0Pw6U&mc_cid=339a84e023&mc_eid=c5d0e37744
- https://www.statnews.com/2020/03/30/crispr-pioneer-doudna-opens-lab-to-run-covid-19-tests/
- https://www.biorxiv.org/content/10.1101/2020.03.13.991307v1

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.